To include your compound in the COVID-19 Resource Center, submit it here.

Enanta reports Phase I data for NASH/PBC candidate

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) reported data from a Phase Ia/Ib trial in 98 healthy volunteers and 48

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE